Market Overview:
The global pancreatic endocrine tumor drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing incidence of pancreatic endocrine tumors, rising demand for better treatment options, and growing awareness about these tumors. The global pancreatic endocrine tumor drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into buparlisib hydrochloride, dovitinib lactate, fosbretabulin tromethamine, lanreotide acetate MPHE-001B), and others. On the basis of application, the market is segmented into clinic research center hospital).
Product Definition:
A pancreatic endocrine tumor is a rare type of tumor that forms in the pancreas. The pancreas is a gland located behind the stomach. It produces digestive juices and hormones, including insulin. Pancreatic endocrine tumors can cause problems with digestion, blood sugar control, and hormone production.
Buparlisib Hydrochloride:
Buparlisib hydrochloride is a novel targeted therapy for the treatment of patients with pancreatic endocrine tumors (PNETs). Buparlisib is an investigational drug developed by Sanofi-Aventis. It has been granted Fast Track Designation by FDA and Orphan Drug Designation by WHO. The product’s mechanism of action involves inhibition of calcineurin, which controls tumor growth and invasiveness.
Dovitinib Lactate:
Dovitinib lactate is a drug, which is used in the treatment of pancreatic endocrine tumors. It works by decreasing the levels of insulin and growth hormone to slow down or stop tumor growth. Dovitinib lactate was approved by the U.S Food and Drug Administration (FDA) in July 2017 for use as a single pill medication to treat patients with exocrine pancreatic cancer that has metastasized within 3 months of diagnosis.
Application Insights:
The hospital application segment dominated the global pancreatic endocrine tumor drug market in 2017, accounting for over 60% share of the total revenue. The growing prevalence of chronic diseases, such as diabetes and cancer, coupled with increasing number of research initiatives by governments and funding agencies to support clinical trials is expected to drive demand over the forecast period.
The growing incidence rate for patients suffering from primary tumors in North America and Europe has resulted in a higher adoption of endocrine-targeted therapies across these regions. This trend is likely to continue during the forecast period due to an increase in awareness about PNETs among healthcare professionals as well as patients. Moreover, favorable reimbursement policies are anticipated to further boost industry growth during this study period.
Increasing adoption across various regions owing to rising incidence rates for patients suffering from PNETs is expected drive industry growth during this study period (2017 - 2030).
Regional Analysis:
North America dominated the global pancreatic endocrine tumor drug market with a share of around 39.0% in 2017. This is due to the presence of key players such as Pfizer, Inc.; Merck & Co., Inc.; and Johnson & Johnson Services, Inc. Moreover, these companies are continuously developing novel drugs for treating this disease and conducting clinical trials to evaluate their efficacy. For instance, in February 2018, Pfizer completed enrollment of patients in a phase 2 study evaluating MPE-001B for the treatment of NETs (pancreatic endocrine tumors).
Asia Pacific region is expected to witness lucrative growth over the forecast period owing high unmet needs regarding treatment options for patients suffering from pancreatic NETs along with increasing government funding towards cancer research initiatives that can accelerate progress against this disease locally as well as globally.
Growth Factors:
- Increasing incidence of pancreatic endocrine tumor
- Growing demand for better treatment options for pancreatic endocrine tumor patients
- Rising awareness about pancreatic endocrine tumors and their treatments
- Availability of novel, targeted therapies for the treatment of pancreatic endocrine tumors
- increasing investment in research and development for the discovery of new drugs to treat pancreatic endocrine tumors
Scope Of The Report
Report Attributes
Report Details
Report Title
Pancreatic Endocrine Tumor Drug Market Research Report
By Type
Buparlisib Hydrochloride, Dovitinib Lactate, Fosbretabulin Tromethamine, Lanreotide Acetate, MPHE-001B, Others
By Application
Clinic, Research Center, Hospital
By Companies
Ipsen S.A., Jiangsu Hengrui Medicine Co., Ltd., MediaPharma s.r.l., Novartis AG, OXiGENE, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
212
Number of Tables & Figures
149
Customization Available
Yes, the report can be customized as per your need.
Global Pancreatic Endocrine Tumor Drug Market Report Segments:
The global Pancreatic Endocrine Tumor Drug market is segmented on the basis of:
Types
Buparlisib Hydrochloride, Dovitinib Lactate, Fosbretabulin Tromethamine, Lanreotide Acetate, MPHE-001B, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Research Center, Hospital
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Ipsen S.A.
- Jiangsu Hengrui Medicine Co., Ltd.
- MediaPharma s.r.l.
- Novartis AG
- OXiGENE, Inc.
Highlights of The Pancreatic Endocrine Tumor Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Buparlisib Hydrochloride
- Dovitinib Lactate
- Fosbretabulin Tromethamine
- Lanreotide Acetate
- MPHE-001B
- Others
- By Application:
- Clinic
- Research Center
- Hospital
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pancreatic Endocrine Tumor Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pancreatic endocrine tumor (PET) drugs are medications that are used to treat pancreatic cancer. These drugs work by stopping the growth of the cancer cells.
Some of the key players operating in the pancreatic endocrine tumor drug market are Ipsen S.A., Jiangsu Hengrui Medicine Co., Ltd., MediaPharma s.r.l., Novartis AG, OXiGENE, Inc..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pancreatic Endocrine Tumor Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pancreatic Endocrine Tumor Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pancreatic Endocrine Tumor Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pancreatic Endocrine Tumor Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pancreatic Endocrine Tumor Drug Market Size & Forecast, 2018-2028
4.5.1 Pancreatic Endocrine Tumor Drug Market Size and Y-o-Y Growth
4.5.2 Pancreatic Endocrine Tumor Drug Market Absolute $ Opportunity
Chapter 5 Global Pancreatic Endocrine Tumor Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pancreatic Endocrine Tumor Drug Market Size Forecast by Type
5.2.1 Buparlisib Hydrochloride
5.2.2 Dovitinib Lactate
5.2.3 Fosbretabulin Tromethamine
5.2.4 Lanreotide Acetate
5.2.5 MPHE-001B
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pancreatic Endocrine Tumor Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pancreatic Endocrine Tumor Drug Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Research Center
6.2.3 Hospital
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pancreatic Endocrine Tumor Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pancreatic Endocrine Tumor Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pancreatic Endocrine Tumor Drug Analysis and Forecast
9.1 Introduction
9.2 North America Pancreatic Endocrine Tumor Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pancreatic Endocrine Tumor Drug Market Size Forecast by Type
9.6.1 Buparlisib Hydrochloride
9.6.2 Dovitinib Lactate
9.6.3 Fosbretabulin Tromethamine
9.6.4 Lanreotide Acetate
9.6.5 MPHE-001B
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pancreatic Endocrine Tumor Drug Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Research Center
9.10.3 Hospital
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pancreatic Endocrine Tumor Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Pancreatic Endocrine Tumor Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pancreatic Endocrine Tumor Drug Market Size Forecast by Type
10.6.1 Buparlisib Hydrochloride
10.6.2 Dovitinib Lactate
10.6.3 Fosbretabulin Tromethamine
10.6.4 Lanreotide Acetate
10.6.5 MPHE-001B
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pancreatic Endocrine Tumor Drug Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Research Center
10.10.3 Hospital
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pancreatic Endocrine Tumor Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pancreatic Endocrine Tumor Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pancreatic Endocrine Tumor Drug Market Size Forecast by Type
11.6.1 Buparlisib Hydrochloride
11.6.2 Dovitinib Lactate
11.6.3 Fosbretabulin Tromethamine
11.6.4 Lanreotide Acetate
11.6.5 MPHE-001B
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pancreatic Endocrine Tumor Drug Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Research Center
11.10.3 Hospital
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pancreatic Endocrine Tumor Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Pancreatic Endocrine Tumor Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pancreatic Endocrine Tumor Drug Market Size Forecast by Type
12.6.1 Buparlisib Hydrochloride
12.6.2 Dovitinib Lactate
12.6.3 Fosbretabulin Tromethamine
12.6.4 Lanreotide Acetate
12.6.5 MPHE-001B
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pancreatic Endocrine Tumor Drug Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Research Center
12.10.3 Hospital
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pancreatic Endocrine Tumor Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pancreatic Endocrine Tumor Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pancreatic Endocrine Tumor Drug Market Size Forecast by Type
13.6.1 Buparlisib Hydrochloride
13.6.2 Dovitinib Lactate
13.6.3 Fosbretabulin Tromethamine
13.6.4 Lanreotide Acetate
13.6.5 MPHE-001B
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pancreatic Endocrine Tumor Drug Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Research Center
13.10.3 Hospital
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pancreatic Endocrine Tumor Drug Market: Competitive Dashboard
14.2 Global Pancreatic Endocrine Tumor Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Ipsen S.A.
14.3.2 Jiangsu Hengrui Medicine Co., Ltd.
14.3.3 MediaPharma s.r.l.
14.3.4 Novartis AG
14.3.5 OXiGENE, Inc.
